Quote:

---

I mean deep pocket stuff is MVC right? N- terminus has to do with LL of course but I don’t think that Madden cared about which point on the seven figure domain LL was bound.

---

Leronlimab binds deep in the receptor where the N terminus resides. Maraviroc doesn't bind the N terminus and binds shallowly. Which has always made me wonder if some ligands might be able to bypass maraviroc in some instances.

Madden knew what he was doing and designed leronlimab with the N terminus in mind. Maybe he thought there was enough room on the N terminus to bind other ligands. Testing out whether ligands would bind along with leronlimab would have been cost prohibitive.